ethyl 2-((tert-butoxycarbonyl)amino)-4-phenylthiazole-5-carboxylate | 302963-98-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: ethyl 2-((tert-butoxycarbonyl)amino)-4-phenylthiazole-5-carboxylate
• 英文别名: 2-tert-butoxycarbonylamino-4-phenyl-thiazole-5-carboxylic acid ethyl ester；ethyl-2-tert-butoxycarbonyloxyamino-4-phenyl-thiazole-5-carboxylate；Ethyl 2-[(tert-butoxycarbonyl)amino]-4-phenyl-1,3-thiazole-5-carboxylate；ethyl 2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-phenyl-1,3-thiazole-5-carboxylate
• CAS: 302963-98-0
• 化学式: C₁₇H₂₀N₂O₄S
• mdl: MFCD15732435
• 分子量: 348.423
• InChiKey: ZOXQRNFZFFTCSQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  106
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ethyl 2-((tert-butoxycarbonyl)amino)-4-phenylthiazole-5-carboxylate 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 生成 2-[[(tert-butyloxy)carbonyl]-amino]-4-phenyl-1,3-thiazole-5-carboxylic acid
  参考文献：
  名称：

  Discovery and initial SAR of 2-amino-5-carboxamidothiazoles as inhibitors of the Src-family kinase p56Lck

  摘要：

  A novel series of 2-amino-5-5carboxamidothiazoles were identified as inhibitors of Lck. Structure-activity studies demonstrate the structural requirements for potent Lck activity. Cyclopropylamide 11d is a potent Lck inhibitor having submicromolar activity in a PBL proliferation assay. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.08.054
• 作为产物：
  描述：

  2-氨基-4-苯基-5-噻唑甲酸乙酯 以90.5%的产率得到ethyl 2-((tert-butoxycarbonyl)amino)-4-phenylthiazole-5-carboxylate
  参考文献：
  名称：

  Cyclic protein tyrosine kinase inhibitors

  摘要：

  新型环状化合物及其盐类，含有此类化合物的药物组合物，以及使用此类化合物治疗蛋白质酪氨酸激酶相关疾病，如免疫和肿瘤疾病的方法。

  公开号：

  US20040054186A1

文献信息

• [EN] 2-ACYLAMINOTHIAZOLE DERIVATIVES<br/>[FR] DERIVES DE 2-ACYLAMINOTHIAZOLE
  申请人：LUNDBECK & CO AS H

  公开号：WO2006032273A1

  公开（公告）日：2006-03-30

  The Invention relates to compounds of the formula I, wherein the variables are as defined in the claims, for use as a medicament. The compounds are A2A-receptor legends and are useful in the treatment of neurological and psychiatric disorders where an A2A-receptor is implicated.

  这项发明涉及到公式I的化合物，其中变量如索赔中定义的那样，用作药物。这些化合物是A2A受体的传奇，并在治疗神经系统和精神疾病方面发挥作用，其中A2A受体起到作用。
• 2-acylaminothiazole derivatives
  申请人：H. Lundbeck A/S

  公开号：US07910613B2

  公开（公告）日：2011-03-22

  The Invention relates to compounds of the formula I, wherein the variables are as defined in the claims, for use as a medicament. The compounds are A2A-receptor legends and are useful in the treatment of neurological and psychiatric disorders where an A2A-receptor is implicated.

  本发明涉及公式I的化合物，其中变量如权利要求所定义，用作药物。这些化合物是A2A受体配体，并且在治疗神经和精神障碍中具有用处，其中涉及A2A受体。
• 2-Acylaminothiazole Derivatives
  申请人：Larsen Mogens

  公开号：US20090137642A1

  公开（公告）日：2009-05-28

  The Invention relates to compounds of the formula I, wherein the variables are as defined in the claims, for use as a medicament. The compounds are A 2A -receptor legends and are useful in the treatment of neurological and psychiatric disorders where an A 2A -receptor is implicated.

  该发明涉及公式I的化合物，其中变量如权利要求中所定义，用作药物。这些化合物是A2A受体配体，并可用于治疗神经系统和精神疾病，在其中A2A受体被涉及。
• Discovery of novel VX-809 hybrid derivatives as F508del-CFTR correctors by molecular modeling, chemical synthesis and biological assays
  作者：Alice Parodi、Giada Righetti、Emanuela Pesce、Annalisa Salis、Bruno Tasso、Chiara Urbinati、Valeria Tomati、Gianluca Damonte、Marco Rusnati、Nicoletta Pedemonte、Elena Cichero、Enrico Millo

  DOI：10.1016/j.ejmech.2020.112833

  日期：2020.12

  Cystic fibrosis (CF) is the autosomal recessive disorder most recurrent in Caucasian populations. It is caused by different mutations in the cystic fibrosis transmembrane regulator protein (CFTR) gene, with F508del being the most common. During the last years, small-molecule therapy chosen to contrast CF relied on compounds that correct CFTR misfolding and ER retention (correctors such as VX-809), or defective channel gating (potentiators such as VX-770). Combination therapy with the two series of drugs has been applied, leading to the approval of several multi-drugs such as Orkambi. Despite this, this treatment proved to be only partially effective making the search for novel modulators an urgent need to contrast CF. Recently, we reported compound 2a as reference compound of a series of aminoarylthiazole-VX-809 hybrid derivatives exhibiting promising F508del-CFTR corrector ability. Herein, we report exploring the docking mode of the prototype VX-809 and of 2a in order to derive useful guidelines for the rational design of novel optimized analogues. To demonstrate experimentally their effective F508del-CFTR-binding and rescuing potential, the most promising derivatives had been synthesized and evaluated in biological assays including YFP functional assay on F508del-CFTR CFBE41o-cells, trans epithelial electrical resistance (TEER) and surface plasmon resonance (SPR). This multidisciplinary strategy led to the discovery of a second series of hybrids including 7j and 7m endowed with higher potency than the prototype.
• 2-ACYLAMINOTHIAZOLE DERIVATIVES
  申请人：H.Lundbeck A/S

  公开号：EP1794157A1

  公开（公告）日：2007-06-13